Transcriptome analysis reveals the clinical significance of CXCL13 in Pan-Gyn tumors

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• Gynecologic and breast tumors (Pan-Gyn) share similarities.
• CXCL13's role in anti-tumor immunity and as a biomarker for immune checkpoint blockade (ICB) therapy is emerging.
• The specific function of CXCL13 in Pan-Gyn requires systematic investigation.

Purpose of the Study:

• To systematically analyze the role of CXCL13 in Pan-Gyn.
• To investigate the correlation between CXCL13 expression and the tumor immune microenvironment (TIME).
• To develop predictive models for patient mortality.

Main Methods:

• Analysis of 2497 Pan-Gyn samples from The Cancer Genome Atlas (TCGA) database.
• Categorization into high and low CXCL13 expression groups with validation using Gene Expression Omnibus (GEO) datasets.
• Evaluation of CXCL13 correlation with TIME using multiple algorithms and nomogram development for mortality prediction.

Main Results:

• High CXCL13 expression in Pan-Gyn correlates with improved clinical outcomes.
• Increased immune cell infiltration and reduced intra-tumor heterogeneity observed in high CXCL13 expressors.
• Developed predictive models demonstrated good discrimination and calibration for 3- and 5-year mortality.

Conclusions:

• This study offers comprehensive insights into CXCL13's role in Pan-Gyn.
• Findings highlight commonalities and differences in CXCL13 expression across these tumor types.
• Results may inform personalized treatment strategies, particularly for ICB therapy.